AVADEL PHARMACEUTICALS PLC | Business Contracts

Indenture, dated as of April 3, 2023, by and between the Issuer, the Company and The Bank of New York Mellon, as Trustee (Filed With SEC on April 5, 2023)

Underwriting Agreement, dated March 29, 2023, by and between the Company and Jefferies LLC (Filed With SEC on March 30, 2023)

Purchase and Sale Agreement, dated March 29, 2023, between Avadel CNS Pharmaceuticals, LLC, the Company, Flamel Ireland Ltd., and RTW Royalty II DAC (Filed With SEC on March 30, 2023)

Form of Exchange Agreement between the Issuer, the Company and certain holders of the 2023 Notes (Filed With SEC on March 29, 2023)

Generic API Supply Agreement by and between Euticals Inc. and Avadel CNS Pharmaceuticals, LLC, dated as of January 2, 2020 (Filed With SEC on March 29, 2023)

Manufacturing Agreement by and between Flamel Ireland Limited and Recipharm Pessac, dated as of October 1, 2022 (Filed With SEC on March 29, 2023)

Description of Securities (Filed With SEC on March 29, 2023)

First Amendment to Employment Agreement, dated as of September 28, 2022, between Avadel Management Corporation and Richard Kim (Filed With SEC on November 9, 2022)

First Amendment to Employment Agreement, dated as of September 28, 2022, between Avadel Management Corporation and Thomas S. McHugh (Filed With SEC on November 9, 2022)

First Amendment to Employment Agreement, dated as of September 28, 2022, between Avadel Management Corporation and Gregory J. Divis (Filed With SEC on November 9, 2022)

Indenture, dated as of April 4, 2022, by and between the Issuer, the Company and The Bank of New York Mellon, as Trustee (Filed With SEC on April 5, 2022)

Avadel Pharmaceuticals plc 2021 Inducement Plan and related equity award agreements (Filed With SEC on March 16, 2022)

Employment Agreement dated as of February 1 (Filed With SEC on March 16, 2022)

Form of Exchange Agreement between Avadel Finance Cayman Limited, Avadel Pharmaceuticals plc and certain holders of its February 2023 Notes (Filed With SEC on March 16, 2022)

Form of Exchange Agreement between the Issuer, the Company and certain holders of the Existing Notes (Filed With SEC on March 16, 2022)

Employment Agreement, dated as of February 15, 2021, by and between Avadel Management Corporation and Richard Kim (Filed With SEC on May 10, 2021)

Exclusive License Agreement by and between Perrigo Pharma International DAC (f/k/a Elan Pharma International Limited) and Flamel Ireland Limited dated September 30, 2015, as... (Filed With SEC on March 9, 2021)

Office Lease Agreement by and between Grove II LLC and Eclat Pharmaceuticals LLC dated October 5, 2015, as amended (Filed With SEC on March 9, 2021)

Avadel Pharmaceuticals plc 2017 Omnibus Incentive Compensation Plan and related equity award agreements (filed (Filed With SEC on March 9, 2021)

Avadel Pharmaceuticals plc 2020 Omnibus Incentive Compensation Plan (filed (Filed With SEC on March 9, 2021)

Employment agreement by and between Avadel Management Corporation and Thomas S. McHugh dated May 15, 2020 (Filed With SEC on August 10, 2020)

Asset Purchase Agreement, dated as of June 30, 2020, by and between Avadel Seller, Seller Parent, Exela Buyer and Buyer Parent (Filed With SEC on July 2, 2020)

Underwriting Agreement, dated April 28, 2020, by and among the Company and Jefferies LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated (Filed With SEC on April 29, 2020)

Registration Rights Agreement, dated February 25, 2020, by and among Avadel Pharmaceuticals plc and the Investors named therein (Filed With SEC on March 16, 2020)

Description of Securities (Filed With SEC on March 16, 2020)

Form of Registration Rights Agreement (Filed With SEC on February 24, 2020)

Securities Purchase Agreement, dated February 20, 2020, by and among Avadel Pharmaceuticals plc and the Investors named therein (Filed With SEC on February 24, 2020)

Employment Agreement dated as of June 5, 2019 between Avadel Management Corporation and Jordan Dubow (Filed With SEC on June 5, 2019)

Amended Employment Agreement dated as of June 3, 2019 between Avadel Management Corporation and Gregory J. Divis (Filed With SEC on June 5, 2019)

Binding Term Sheet between Avadel US Holdings, Inc. and Avadel Specialty Pharmaceuticals LLC (Filed With SEC on February 14, 2019)

First Supplemental Indenture, dated as of February 6, 2019, by and among Avadel Finance Cayman Limited, Avadel Pharmaceuticals plc, and The Bank of New York Mellon (Filed With SEC on February 7, 2019)

Employment Termination and Release Agreement, dated December 30, 2018, between Avadel Management Corporation, Avadel Pharmaceuticals plc and Michael S. Anderson (Filed With SEC on January 3, 2019)

Asset Purchase Agreement by and among Cerecor, Inc. and Avadel Pharmaceuticals (USA), Inc., Avadel Pediatrics, Inc., FSC Therapeutics, LLC, Avadel US Holdings, Inc. and Avadel... (Filed With SEC on March 16, 2018)

License and Development Agreement by and between Cerecor, Inc. and Flamel Ireland Limited operating under the trade name of Avadel Ireland dated as of February 16, 2018 (Filed With SEC on March 16, 2018)

Guarantee by Avadel US Holdings, Inc. and Avadel Pharmaceuticals plc in favor of Deerfield CSF, LLC, Peter Steelman and James Flynn dated as of February 16, 2018 (Filed With SEC on March 16, 2018)

Guarantee by Armistice Capital Master Fund, Ltd. in favor of Avadel US Holdings, Inc. dated as of February 16, 2018 (Filed With SEC on March 16, 2018)

Letter Agreement, dated February 22, 2018, between Breaking Stick Holdings, LLC and Avadel Pharmaceuticals plc (Filed With SEC on February 22, 2018)

Indenture, dated as of February 16, 2018, by and between the Issuer, the Company and The Bank of New York Mellon, as Trustee (Filed With SEC on February 16, 2018)

Letter Agreement dated February 16, 2018 between Avadel Pharmaceuticals plc and The Bank of New York Mellon (Filed With SEC on February 16, 2018)

Form of U.S. Restricted Stock Unit Award Grant Notice and Agreement (Filed With SEC on December 8, 2017)

Master Manufacturing Services Agreement by and between Patheon UK Limited and clat Pharmaceuticals L.L.C. dated as of November 8, 2012 (Filed With SEC on November 9, 2017)

Renaissance Agreements Assignment and Assumption Agreement by and between Avadel Specialty Pharmaceuticals, LLC and Serenity Pharmaceuticals, LLC dated as of September 1, 2017 (Filed With SEC on November 9, 2017)

Manufacturing Agreement by and between Renaissance Lakewood, LLC (formerly DPT Lakewood, LLC) and Serenity Pharmaceuticals, LLC dated as of July 14, 2014 (Filed With SEC on November 9, 2017)

Exclusive License and Assignments Agreement by and between Avadel Specialty Pharmaceuticals, LLC and Serenity Pharmaceuticals, LLC dated as of September 1, 2017 (Filed With SEC on November 9, 2017)

Exclusive Right of Negotiation Agreement by and between Avadel Specialty Pharmaceuticals, LLC and Serenity Pharmaceuticals, LLC dated as of August 11, 2017 (Filed With SEC on November 9, 2017)

Employment Agreement by and between Avadel Management Corporation and Phillandas T. Thompson dated August 15, 2017 (Filed With SEC on November 9, 2017)

Employment Agreement by and between Avadel Management Corporation and Michael F. Kanan dated September 5, 2017 (Filed With SEC on November 9, 2017)

Employment Agreement by and between Avadel Management Corporation and Sandra Hatten dated August 15, 2017 (Filed With SEC on November 9, 2017)

Employment Agreement by and between Avadel Management Corporation and Gregory J. Divis dated September 5, 2017 (Filed With SEC on November 9, 2017)

Employment Agreement by and between Avadel Management Corporation and Michael S. Anderson dated August 15, 2017 (Filed With SEC on November 9, 2017)

Form of Stock Option Agreement (Filed With SEC on June 30, 2017)

Company Name and Address [# of shares] [City] [Date] (Filed With SEC on March 28, 2017)

GUARANTY (Filed With SEC on March 28, 2017)

EMPLOYMENT AGREEMENT (Filed With SEC on March 28, 2017)

AVADEL PHARMACEUTICALS LIMITED The Acquiring Company FLAMEL TECHNOLOGIES S.A. The Acquired Company COMMON DRAFT TERMS OF CROSS-BORDER MERGER Dated 29 June 2016 (Filed With SEC on July 1, 2016)

AVADEL PHARMACEUTICALSLIMITED The AcquiringCompany FLAMEL TECHNOLOGIESS.A. The Acquired Company (Filed With SEC on June 2, 2016)

Employment Agreement, dated as of May 24, 2016 between Flamel Technologies S.A. and Michael S. Anderson (Filed With SEC on May 27, 2016)

Employment Agreement, dated as of May 23, 2016 between Flamel Technologies S.A. and Michael F. Kanan (Filed With SEC on May 27, 2016)

EMPLOYMENT AGREEMENT (Filed With SEC on March 15, 2016)

CONFIDENTIAL TREATMENT REQUESTED THEPORTIONS OF THIS AGREEMENT MARKED WITH ASTERISKS WITHIN BRACKETS (“[***]”) HAVE BEEN OMITTED PURSUANT TO A REQUESTFOR CONFIDENTIAL... (Filed With SEC on March 15, 2016)

LEASE (Filed With SEC on March 15, 2016)

OFFICELEASE (Filed With SEC on March 15, 2016)

Dated the 3rd dayof July 2015 Channor Limited (Filed With SEC on March 15, 2016)

EMPLOYMENT AGREEMENT (Filed With SEC on March 15, 2016)

FLAMELTECHNOLOGIES SociétéAnonyme au capital de 4 901 727 euros SiègeSocial : ParcClub du Moulin à Vent 33,avenue du Docteur Georges Lévy 69200VENISSIEUX R.C.S.LYON... (Filed With SEC on March 15, 2016)

MEMBERSHIP INTEREST PURCHASE AGREEMENT by and among FSC HOLDING COMPANY, LLC, a Delaware limited liability company, FSC THERAPEUTICS, LLC, a Delaware limited liability company,... (Filed With SEC on March 15, 2016)

FLAMELTECHNOLOGIES SOCIETE ANONYME AU CAPITAL DE 4 636 011 EUROS SiegeSocial : ParcClub du Moulin A Vent 33,avenue du Docteur Georges Lévy 69200VENISSIEUX R.C.S.LYON 379.001.530... (Filed With SEC on March 15, 2016)

[xxxx] free shares of the Company, (Filed With SEC on March 15, 2016)

FLAMELTECHNOLOGIES SOCIETE ANONYME AU CAPITAL DE 4 636 011 EUROS SiègeSocial : ParcClub du Moulin A Vent 33,avenue du Docteur Georges Lévy 69200VENISSIEUX R.C.S.LYON 379.001.530... (Filed With SEC on March 15, 2016)

FLAMELTECHNOLOGIES SOCIETE ANONYME WITH A STATED CAPITAL OF 5,029,783 EUROS RegisteredOffice: ParcClub du Moulin A Vent 33,avenue du Docteur Georges Lévy 69200VENISSIEUX... (Filed With SEC on March 15, 2016)

AVADEL PHARMACEUTICALS PLC (70)